Alongside its previously demonstrated selective cytotoxic and chemosensitizing effects on multidrug-resistant breast cancer cells while sparing NIH/3T3 fibroblasts, indicating a favorable therapeutic window, these structural and pharmacological traits strongly support the evaluation of 2,3′-dihydroxy-5′-methoxystilbene, derived from Paphiopedilum dianthum as a potential AKT-targeting and redox-modulating agent in NSCLC. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.